|
US2017348270A1
|
|
Fumarate esters
|
|
US9849125B1
|
|
Anti-overingestion dosage forms
|
|
US2017065613A1
|
|
Non-systemic topical compositions comprising corticosteroids
|
|
US9943513B1
|
|
Opioid abuse deterrent dosage forms
|
|
WO2017040272A1
|
|
Fumarate ester dosage forms
|
|
US2017056359A1
|
|
Fumarate ester dosage forms
|
|
WO2017151184A1
|
|
Fumarate ester dosage forms
|
|
WO2016205172A1
|
|
Soft lozenges comprising corticosteroids
|
|
WO2016111731A1
|
|
Abuse-deterrent opioids
|
|
US2016101059A1
|
|
Controlled release fumarate esters
|
|
AU2015328676A1
|
|
Controlled release enteric soft capsules of fumarate esters
|
|
CA2950444A1
|
|
Enhanced bioavailability of polyunsaturated fatty acids
|
|
US2015366814A1
|
|
All-natural enteric soft capsules comprising active ingredients
|
|
WO2015195989A1
|
|
Enteric soft capsule compositions
|
|
US2015366813A1
|
|
Liquid-filled immediate release soft gelatin capsules
|
|
WO2015130998A1
|
|
Controlled release enteric soft capsules of fumarate esters
|
|
US2015108033A1
|
|
Pharmaceutical compositions for poorly soluble active ingredients
|
|
EP2968186A1
|
|
Silk-based capsules
|
|
EP2279729A2
|
|
Controlled release preparations
|
|
EP2772250A1
|
|
Enteric composition for the manufacture of soft capsule wall
|
